Abstract:Purpose To investigate the role of contrast-enhanced magnetic resonance imaging (CE-MRI) radiomics for pretherapeutic prediction of the response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Methods One hundred and twenty-two HCC patients (objective response, n = 63; non-response, n = 59) who received CE-MRI examination before initial TACE were retrospectively recruited and randomly divided into a training cohort ( n = 85) and a validation cohort ( n = 37). All HCCs were manually segmented on arterial, venous and delayed phases of CE-MRI, and total 2367 radiomics features were extracted. Radiomics models were constructed based on each phase and their combination using logistic regression algorithm. A clinical-radiological model was built based on independent risk factors identified by univariate and multivariate logistic regression analyses. A combined model incorporating the radiomics score and selected clinical-radiological predictors was constructed, and the combined model was presented as a nomogram. Prediction models were evaluated by receiver operating characteristic curves, calibration curves, and decision curve analysis. Results Among all radiomics models, the three-phase radiomics model exhibited better performance in the training cohort with an area under the curve (AUC) of 0.838 (95% confidence interval (CI), 0.753 - 0.922), which was verified in the validation cohort (AUC, 0.833; 95% CI, 0.691 - 0.975). The combined model that integrated the three-phase radiomics score and clinical-radiological risk factors (total bilirubin, tumor shape, and tumor encapsulation) showed excellent calibration and predictive capability in the training and validation cohorts with AUCs of 0.878 (95% CI, 0.806 - 0.950) and 0.833 (95% CI, 0.687 - 0.979), respectively, and showed better predictive ability ( P = 0.003) compared with the clinical-radiological model (AUC, 0.744; 95% CI, 0.642 - 0.846) in the training cohort. A nomogram based on the combined model achieved good clinical utility in predicting the treatment efficacy of TACE. Conclusion CE-MRI radiomics analysis may serve as a promising and noninvasive tool to predict therapeutic response to TACE in HCC, which will facilitate the individualized follow-up and further therapeutic strategies guidance in HCC patients.

Comparison of contrast-enhanced ultrasonography and MRI results obtained by expert and novice radiologists indicating short-term response after transarterial chemoembolisation for hepatocellular carcinoma

[Application Value of Contrast-Enhanced Ultrasonography for Assessing the High-Risk Population of Hepatic Malignant Tumor].

Assessment of Hepatocellular Carcinoma Undergoing Trans-Catheter Arterial Chemoembolization with Functional Magnetic Resonance Imaging

Interobserver and inter-modalities agreement of contrast-enhanced ultrasound liver imaging reporting and data system(CEUS LI-RADS) and magnetic resonance imaging liver imaging reporting and data system(MRI LI-RADS) for hepatocellular carcinoma in high-risk patients

Contrast-enhanced Ultrasound in the Characterization of Hepatocellular Carcinomas Treated by Ablation: Comparison with Contrast-Enhanced Magnetic Resonance Imaging.

1287: A Comparative Study of Contrast-Enhanced Ultrasound and Contrast-Enhanced MRI in Evaluating the Therapeutic Response of Microwave Thermal Ablation for Liver Malignances

Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer

Contrast-Enhanced Ultrasound in Residual Tumor of Hepatocellular Carcinoma Following Transarterial Chemoembolization: is It Helpful for Tumor Response?

Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: A Meta-analysis.

Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis

Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound

Evaluation of the Contrast-Enhanced Ultrasound Nonradiation Treatment Response Assessment LI-RADS v2024 Using Data From a Multi-Center Transarterial Chemoembolization Study

Parametric Imaging with Contrast-Enhanced Ultrasound: Usefulness for Characterization of Dynamic Effects of Microvascularization for Hepatocellular Carcinoma and Focal Nodular Hyperplasia.

Diagnostic Efficacy of Contrast‐Enhanced MRI in Detecting Residual or Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization: A Systematic Review and Meta‐analysis

Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China.

Clinical value of transhepatic arterial contrast-enhanced ultrasonography in assessing efficacy of transarterial chemoembolization for hepatocellular carcinoma

Comparison of Contrast-Enhanced Ultrasound and Contrast-Enhanced Computed Tomography in Evaluating the Treatment Response to Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma Using Modified RECIST.

Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma

Value of Texture Analysis Based on Enhanced MRI for Predicting an Early Therapeutic Response to Transcatheter Arterial Chemoembolisation Combined with High-Intensity Focused Ultrasound Treatment in Hepatocellular Carcinoma

Application of contrast-enhanced ultrasound and enhanced CT in diagnosis of liver cancer and evaluation of radiofrequency ablation

Intraarterial Contrast-Enhanced Ultrasound to Predict the Short-Term Tumour Response of Hepatocellular Carcinoma to Transarterial Chemoembolization with Lipiodol.